PMID- 37315473
OWN - NLM
STAT- MEDLINE
DCOM- 20230714
LR  - 20230718
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 17
IP  - 7
DP  - 2023 Jul
TI  - Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose 
      cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus 
      White patients with type 2 diabetes mellitus.
PG  - 102804
LID - S1871-4021(23)00100-5 [pii]
LID - 10.1016/j.dsx.2023.102804 [doi]
AB  - BACKGROUND: The study aimed to assess the treatment effects of the two 
      medications on cardiovascular and kidney outcomes in Asian compared with White 
      patients with type 2 diabetes mellitus (T2DM). METHODS: MEDLINE, EMBASE, and 
      CENTRAL were searched up to October 31, 2022. We included the trials that 
      assessed the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RA) or 
      sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus placebo in Asian and 
      White patients with T2DM on major adverse cardiovascular events (MACE) and kidney 
      outcomes. The Bucher method was used to perform an indirect comparison for 
      estimating the differences in treatment effects of GLP-1 RA and SGLT2i between 
      Asian versus White patients. Interaction tests were also performed for 
      treatment-by-race to assess the potential effect modification by race. RESULTS: 
      We included 22 publications from 13 randomized trials. For MACE, there were no 
      differences in treatment effects of GLP-1 RA (HR = 0.84, 95% CI: 0.68-1.04) or 
      SGLT2i (HR = 0.90, 95% CI: 0.72-1.13) in Asian versus White patients. No 
      differences in treatment effects of SGLT2i on kidney outcomes in Asian versus 
      White patients were found (HR = 1.01, 95% CI: 0.75-1.36). There was no 
      significant effect modification by race on cardiovascular and kidney outcomes. 
      CONCLUSIONS: There were no significant differences in treatment effects of GLP-1 
      RA or SGLT2i for MACE between Asian and White patients with T2DM. Likewise, no 
      significant differences in treatment effects of SGLT2i on kidney outcomes were 
      found between Asian and White patients.
CI  - Copyright (c) 2023 Research Trust of DiabetesIndia (DiabetesIndia) and National 
      Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. 
      All rights reserved.
FAU - Zhang, Jingyi
AU  - Zhang J
AD  - Center for Clinical Epidemiology and Methodology (CCEM), Guangdong Second 
      Provincial General Hospital, Guangzhou, China.
FAU - Van Spall, Harriette Gc
AU  - Van Spall HG
AD  - Department of Health Research Methods, Evidence, and Impact (HEI), McMaster 
      University, Hamilton, ON, Canada; Department of Medicine, McMaster University, 
      Hamilton, ON, Canada.
FAU - Li, Likang
AU  - Li L
AD  - Center for Clinical Epidemiology and Methodology (CCEM), Guangdong Second 
      Provincial General Hospital, Guangzhou, China.
FAU - Khan, Mohammad Shahzeb
AU  - Khan MS
AD  - Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
FAU - Pandey, Ambarish
AU  - Pandey A
AD  - Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
FAU - Thabane, Lehana
AU  - Thabane L
AD  - Department of Health Research Methods, Evidence, and Impact (HEI), McMaster 
      University, Hamilton, ON, Canada; Father Sean O'Sullivan Research Centre, St 
      Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
FAU - Bai, Xuerui
AU  - Bai X
AD  - Department of Epidemiology, School of Medicine, Jinan University, Guangzhou, 
      China.
FAU - Wang, Yaoyao
AU  - Wang Y
AD  - Department of Epidemiology, School of Medicine, Jinan University, Guangzhou, 
      China.
FAU - Lip, Gregory Yh
AU  - Lip GY
AD  - Liverpool Centre for Cardiovascular Sciences at University of Liverpool, 
      Liverpool John Moores University, Liverpool Heart & Chest Hospital, Liverpool, 
      United Kingdom; Department of Clinical Medicine, Aalborg University, Aalborg, 
      Denmark.
FAU - Li, Guowei
AU  - Li G
AD  - Center for Clinical Epidemiology and Methodology (CCEM), Guangdong Second 
      Provincial General Hospital, Guangzhou, China; Department of Health Research 
      Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, ON, Canada; 
      Father Sean O'Sullivan Research Centre, St Joseph's Healthcare Hamilton, 
      Hamilton, ON, Canada. Electronic address: lig28@mcmaster.ca.
LA  - eng
PT  - Journal Article
DEP - 20230602
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Humans
MH  - *Cardiovascular Diseases/prevention & control/chemically induced
MH  - *Diabetes Mellitus, Type 2/drug therapy/chemically induced
MH  - *Glucagon-Like Peptide-1 Receptor/agonists
MH  - Hypoglycemic Agents/therapeutic use
MH  - Kidney
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MH  - White People
MH  - Asian
OTO - NOTNLM
OT  - Cardiovascular outcomes
OT  - Glucagon-like peptide-1 receptor agonists
OT  - Kidney outcomes
OT  - Race
OT  - Sodium-glucose cotransporter 2 inhibitors
OT  - Type 2 diabetes mellitus
COIS- Declaration of competing interest All authors declare no competing interests.
EDAT- 2023/06/15 01:08
MHDA- 2023/07/14 13:06
CRDT- 2023/06/14 18:06
PHST- 2023/01/09 00:00 [received]
PHST- 2023/05/08 00:00 [revised]
PHST- 2023/06/02 00:00 [accepted]
PHST- 2023/07/14 13:06 [medline]
PHST- 2023/06/15 01:08 [pubmed]
PHST- 2023/06/14 18:06 [entrez]
AID - S1871-4021(23)00100-5 [pii]
AID - 10.1016/j.dsx.2023.102804 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2023 Jul;17(7):102804. doi: 10.1016/j.dsx.2023.102804. Epub 
      2023 Jun 2.